Regulation of inflammatory pathways by cannabigerol in the collagen induced arthritis model in rats
Frontiers in Pharmacology · 28.10.2025 · 16
DOI: 10.3389/fphar.2025.1705962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.10.2025. Verfasst von Monika Šteigerová und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
This study aims to assess the anti-inflammatory properties of cannabigerol (CBG) in collagen-induced arthritis (CIA) model in rats, and to determine which inflammatory signaling pathways it affects. Study design Rats were randomized into four groups: placebo (PCB)–p.o. Treated with 1 mL of 0.9% saline once daily, CBG–p.o. Treated with 30 mg of CBG/day, glucocorticoids (GC)–p.o. Treated with methylprednisolone 0.5 mg/kg/day, and negative control (CO)–p.o. Treated with 1 mL of 0.9% saline once daily. CIA was induced in the PCB, GC, and CBG groups. The effect of CBG was assessed by clinical scoring, paw width measurements, ELISA, and analysis of gene (qPCR) and protein (Western blot) expression of selected inflammatory markers in blood and synovial membrane.
Results
Clinical scores showed significant improvement in the CBG vs. PCB on day 29 and in the GC vs. PCB on days 24, 27, and 29. MMP-3 levels in serum were significantly reduced in the GC vs. PCB. CBG demonstrated a selective anti-inflammatory and immunomodulatory profile, notably through the downregulation of key signaling molecules such as TLRs, systemic NF-κB p65, STAT-3, and inflammasome-related components including NLRP1A, NLRP3, AIM2, gasdermin D, and caspase-1. It also reduced IL-1β and TNF expression during the early phase of disease and increased expression of the anti-apoptotic gene BCL-2.
Conclusion
Our findings indicate that CBG modulates distinct components of the inflammatory signaling pathways, and its effects translated into significant improvement in clinical scoring based on swelling, erythema, stiffness in rat CIA model.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
- Department of Chemical Engineering, Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Czechia.
- Institute of Histology and Embryology, First Faculty of Medicine, Charles University, Prague, Czechia.
- Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
Zitieren
APA
Šteigerová, M., Sklenárová, M., Bazyuk, M., Záveský, L., Jelínek, P., Arora, M., Stránský, D., Kučera, T., Sepodes, B., Šoóš, M., Šíma, M., & Slanař, O. (2025). Regulation of inflammatory pathways by cannabigerol in the collagen induced arthritis model in rats. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1705962
Vancouver
Šteigerová M, Sklenárová M, Bazyuk M, Záveský L, Jelínek P, Arora M, et al. Regulation of inflammatory pathways by cannabigerol in the collagen induced arthritis model in rats. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1705962
BibTeX
@article{teigerov2025,
author = {Šteigerová, Monika and Sklenárová, Michaela and Bazyuk, Mykhaylo and Záveský, Luděk and Jelínek, Petr and Arora, Mahak and Stránský, Daniel and Kučera, Tomáš and Sepodes, Bruno and Šoóš, Miroslav and Šíma, Martin and Slanař, Ondřej},
title = {Regulation of inflammatory pathways by cannabigerol in the collagen induced arthritis model in rats},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1705962}
}
EUVIMED